According to a new report, published by KBV research, The Global Tuberculosis Diagnostics Market size is expected to reach $3 billion by 2031, rising at a market growth of 4.7% CAGR during the forecast period.
The Diagnostic Laboratories segment led the Global Tuberculosis Diagnostics Market by End Use in 2023; thereby, achieving a market value of $1.31 billion by 2031. Diagnostic laboratories are the primary centers for administering comprehensive TB tests, including molecular diagnostics, culture, and drug susceptibility testing (DST), due to their advanced technologies and specialized personnel.
The Diagnostic Laboratories segment led the Global Tuberculosis Diagnostics Market by End Use in 2023; thereby, achieving a market value of $1.31 billion by 2031. Diagnostic laboratories are the primary centers for administering comprehensive TB tests, including molecular diagnostics, culture, and drug susceptibility testing (DST), due to their advanced technologies and specialized personnel.
The Detection of Latent Infection (Skin Test & IGRA) segment is growing at a CAGR of 4.1 % during the forecast period. This dominant position can be attributed to the extensive use of these tests in screening programs, particularly among high-risk populations such as healthcare personnel and individuals with compromised immune systems.
Full Report: https://www.kbvresearch.com/tuberculosis-diagnostics-market/
The North America region dominated the Global Tuberculosis Diagnostics Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $885 million by 2031. The Europe region is anticipated to grow at a CAGR of 4.4% during (2024 - 2031). Additionally, The Asia Pacific region would witness a CAGR of 5.2% during (2024 - 2031).
By End Use
By Type
By Geography
Unique Offerings 
